This disclosure provides a gene expression-based method for determining whether a subject having sepsis has an Inflammopathic phenotype, an Adaptive phenotype or a Coagulopathic phenotype. A kit for performing the method is also provided.

The present invention provides a method of detecting multiple analytes in a sample, wherein said analytes have varying levels of abundance in the sample, said method comprising: (i) providing multiple aliquots from the sample; and (ii) in each aliquot, detecting a different subset of the analytes by performing a separate multiplex assay for each aliquot, wherein the analytes in each subset are selected based on their predicted abundance in the sample.

Provided herein are a set of primers and probes for detecting rotavirus. The set of primers and probes includes at least one forward primer selected from the group including SEQ ID NOS: 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104, 107, 110, 113, 116, 119, 122, 125, 128, 131, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 204, 207, 210, and combinations thereof; at least one reverse primer selected from the group including SEQ ID NOS: 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 205, 208, 211, and combinations thereof; and at least one probe selected from the group including SEQ ID NOS: 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 206, 209, 212, and combinations thereof. Also provided herein is a method for detecting rotavirus using the set of primers and probes.

An aspect of the invention provides a method for analysing the Duchenne Muscular Dystrophy (DMD) gene in a sample containing genetic material of a subject, wherein the method detects the presence or absence of at least exons 7, 43, 44, 45, 46, 49, 50, 51, 52 and 54 of the DMD gene in the genetic material of the subject, wherein the detection of the presence or absence of the exons comprises multiplex polymerase-based nucleic acid amplification. Another aspect of the invention provides a method for analysing the DMD gene in a sample containing genetic material of a subject, wherein the method detects the presence or absence of at least exons 7, 43, 44, 45, 46, 49, 50, 51, 52 and 54 of the DMD gene in the genetic material of the subject, and wherein the sample is blood. Additional aspects of the invention provide tools applicable in the disclosed methods, such as primers, primer pairs, primer pair sets, oligonucleotide probes and probe sets, as well as compositions and kits containing the same.

A real-time fluorescence RT-PCR detection method and a kit for a novel coronavirus 2019-nCoV. Specifically, the present invention relates to a kit and a method for detecting the nucleic acid of an E gene of the novel coronavirus 2019-nCoV. The kit and the method have extremely high sensitivity and specificity, and can significantly improve the accuracy of virus identification.

The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as “tracers”) for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.

Provided are methods and compositions for preparing a library of target nucleic acid sequences that are useful for assessing gene mutations for oncology biomarker profiling of samples. In particular, a target-specific primer panel is provided that allows for selective amplification of oncology biomarker target sequences in a sample. In one aspect, the invention relates to target-specific primers useful for selective amplification of one or more target sequences associated with oncology biomarkers from two or more sample types. In some aspects, amplified target sequences obtained using the disclosed methods, and compositions can be used in various processes including nucleic acid sequencing and used to detect the presence of genetic variants of one or more targeted sequences associated with oncology.

Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5′-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.

Methods for construction of DNA origami nanostructures, as well as for binding, isolation, linking, and deep sequencing information, such as both of TCR alpha and beta CDR3 mRNA, from individual cells within a mixed population of cells without the need for single cell sorting (FIG. 1).

The present invention provides methods and compositions that are useful for assessing gene expression for tumor immune response profile of a sample. In particular, a target-specific primer panel is provided that allows for selective amplification of immune response target sequences in a sample. In one aspect, the invention relates to target-specific primers useful for selective amplification of one or more target sequences associated with immune response. In some aspects, amplified target sequences obtained using the disclosed methods, and compositions can be used in various processes including nucleic acid sequencing and used to detect the presence of genetic variants and/or expression levels of one or more targeted sequences associated with immune response.